US Stock MarketDetailed Quotes
OTLK Outlook Therapeutics
- 7.700
- -0.300-3.75%
Trading May 9 13:48 ET
179.40MMarket Cap-1925P/E (TTM)
8.180High7.630Low124.20KVolume8.180Open8.000Pre Close961.43KTurnover1.12%Turnover RatioLossP/E (Static)23.30MShares40.60052wk High-7.37P/B85.21MFloat Cap4.00452wk Low--Dividend TTM11.07MShs Float219.200Historical High--Div YieldTTM6.88%Amplitude4.004Historical Low7.740Avg Price1Lot Size
About Outlook Therapeutics Company
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
Company Profile
SymbolOTLK
Company NameOutlook Therapeutics
Listing DateJun 13, 2016
Founded2010
CEOMr. C. Russell Trenary, III
MarketNASDAQ
Employees24
Securities TypeOrdinary Shares
Fiscal Year Ends09-30
Address485 Route 1 South,Building F, Suite 320
CityIselin
ProvinceNew Jersey
CountryUnited States of America
Zip Code08852
Phone1-609-619-3990
Company Executives
- Name
- Position
- Salary
- C. Russell Trenary, III
- President, Chief Executive Officer and Director
- 1.76M
- Jeff Evanson
- Chief Commercial Officer
- 718.20K
- Lawrence A. Kenyon
- Chief Financial Officer, Executive Vice President, Treasurer, Secretary, Principal Accounting Officer and Director
- 1.86M
- Ralph H. Thurman
- Executive Chairman of the Board
- 242.50K
- Julian S. Gangolli
- Independent Director
- 112.50K
- Dr. Gerd U. Auffarth, M.D.
- Independent Director
- 79.00K
- Yezan Munther Haddadin
- Independent Director
- 110.00K
- Faisal G. Sukhtian
- Independent Director
- 113.00K
- Kurt J. Hilzinger
- Independent Director
- 95.00K
- Andong Huang
- Independent Director
- 75.00K
- Dr. Julia A. Haller, M.D.
- Independent Director
- 79.00K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg